Sector Chart COMPASS Pathways plc

Stocks

CMPS

US20451W1018

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-09-17 EDT			5-day change	1st Jan Change
15.00 ^USD	+8.70%		+5.49%	+117.39%

09-09	Compass Pathways Reports New 52-Week Topline Open-Label Data From Phase 3 COMP005 Trial Demonstrating Additional Benefit From Another COMP360 Dose In Part C Extending Durability Out To 1 Year	CI
08-06	B. Riley Adjusts COMPASS Pathways Price Target to $22 From $17, Maintains Buy Rating	MT

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Sector Other Biotechnology & Medical Research

	Capi.	Sales Growth	Profitability	Finances	EV / Sales	P/E
COMPASS PATHWAYS PLC	2.08B	-	-	-	-	-
LONZA GROUP AG	46.18B
IQVIA HOLDINGS INC.	44.35B
REVOLUTION MEDICINES, INC.	42.21B	-	-	-	-	-
BEONE MEDICINES AG	40.19B
CELLTRION, INC.	29.83B